ネクセラファーマ(株)【4565】の掲示板 2016/04/23〜2016/04/24

アラガンだけでもこんなにすごいの？？総額3000億とか、10%以上のロイヤルテイとか。

Allergan

Global R&D and commercialisation agreement (2016) under which Allergan licenses exclusive global rights to Heptares’ broad portfolio of novel subtype-selective muscarinic receptor agonists in development for the treatment of major neurological diseases, including Alzheimer’s disease. Heptares received $125 million upfront, and is eligible for milestone payments of up to approximately $3.25 billion, plus up to double-digit royalties.
Allergan is also committing up to $50 million to joint R&D programme aimed at advancing multiple candidates through Phase 2 studies. Allergan will be responsible for the development of licensed compounds upon initiation of Phase 2b studies and for subsequent manufacturing and commercialization of the products.